
The candidate vaccine’s next steps will be going through the FDA’s Biologics License Application process.
Privigen is indicated for the treatment of both primary immunodeficiency and chronic immune thrombocytopenic purpura and will be launched in the first quarter of 2008.
The first proline-stabilized intravenous immunoglobulin (IVIG) that can be stored at room temperature and does not require reconstitution has been approved by the FDA. Privigen (Immune Globulin Intravenous [Human] 10% Liquid), from CSL Behring, is indicated for the treatment of both primary immunodeficiency and chronic immune thrombocytopenic purpura and will be launched in the first quarter of 2008.
To see more Hot off the Press news articles,
To go to the Drug Topics homepage,






